Saposin C
- Generic Name
- Saposin C
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 2N62LTC861
- Background
Saposin C is a lysosomal protein. Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy. BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.
Bexion Pharmaceuticals Presents BXQ-350 Data in Metastatic Colorectal Cancer at ASCO GI 2025
• Bexion Pharmaceuticals will present a poster on BXQ-350 in combination with mFOLFOX7 and bevacizumab for metastatic colorectal cancer at the ASCO GI 2025.
• BXQ-350 is a first-in-class biologic that modulates sphingolipid metabolism and has shown single-agent activity across multiple solid tumor types.
• The Phase 1b/2 study evaluates BXQ-350 with standard of care in newly diagnosed metastatic colorectal cancer patients, with plans to proceed to a randomized, double-blinded, placebo-controlled phase.
• Bexion is also exploring BXQ-350's potential in chemotherapy-induced peripheral neuropathy, addressing a significant unmet need.
Bexion Pharmaceuticals Completes Enrollment in Phase 1b/2 Trial of BXQ-350 for Metastatic Colorectal Cancer
• Bexion Pharmaceuticals has completed enrollment in the open-label phase of its ASIST trial, evaluating BXQ-350 in metastatic colorectal cancer.
• The ASIST trial investigates BXQ-350 combined with mFOLFOX7 and bevacizumab as a first-line treatment for mCRC, potentially reducing chemotherapy-induced neuropathy.
• BXQ-350, a first-in-class biologic, has demonstrated a robust safety profile and single-agent activity across various solid tumors in earlier phase 1 trials.
• The study's primary endpoints include determining the recommended phase 2 dose, incidence of adverse events, and objective response rate, with an estimated completion in April 2029.
BXQ-350 Demonstrates Tolerability and Clinical Activity in Advanced Solid Tumors
• Phase 1 trial data show BXQ-350, a nanovesicle formulation of saposin C, is well-tolerated in patients with advanced solid tumors and high-grade glioma.
• The study, involving 86 patients, found no dose-limiting toxicities and identified nausea and fatigue as the most common treatment-related adverse events.
• Eight patients achieved progression-free survival of at least 6 months, with two experiencing partial responses and two remaining progression-free for 7 years.
• An ongoing phase 1b/2 trial is evaluating BXQ-350 in combination with standard-of-care therapy for newly diagnosed metastatic colorectal cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath